Hostname: page-component-8448b6f56d-tj2md Total loading time: 0 Render date: 2024-04-23T19:35:44.469Z Has data issue: false hasContentIssue false
  • English
  • Français

Meta-analysis of double-blind placebo-controlled trials of antidepressants and benzodiazepines for patients with panic disorders

Published online by Cambridge University Press:  09 July 2009

Greg Wilkinson ,
Matteo Balestrieri ,
Mirella Ruggeri  and
Cesario Bellantuono
Greg Wilkinson*
Affiliation:
Academic Sub-department of Psychological Medicine, North Wales Hospital, Denbigh, Wales, Servizio di Psicologia Medica, Istituto di Psichiatria, Università di Verona, Italy
Matteo Balestrieri
Affiliation:
Academic Sub-department of Psychological Medicine, North Wales Hospital, Denbigh, Wales, Servizio di Psicologia Medica, Istituto di Psichiatria, Università di Verona, Italy
Mirella Ruggeri
Affiliation:
Academic Sub-department of Psychological Medicine, North Wales Hospital, Denbigh, Wales, Servizio di Psicologia Medica, Istituto di Psichiatria, Università di Verona, Italy
Cesario Bellantuono
Affiliation:
Academic Sub-department of Psychological Medicine, North Wales Hospital, Denbigh, Wales, Servizio di Psicologia Medica, Istituto di Psichiatria, Università di Verona, Italy
*
1Address for correspondence: Dr Greg Wilkinson, Academic Sub-department of Psychological Medicine, North Wales Hospital, Denbigh, Clwyd, LL16 5SS, Wales, UK.
Get access Rights & Permissions [Opens in a new window]

Synopsis

Meta-analysis of 19 double-blind placebo-controlled trials of antidepressants (N = 13) and benzodiazepines (N = 6) for patients with panic disorders showed that active treatment had 25% greater success rate than placebo over a mean duration of 14 weeks. There were no statistically significant differences observed between treatment sub-groups (antidepressants – mean duration 16 weeks; and benzodiazepines – mean duration 7 weeks). On this basis antidepressants and benzodiazepines prescribed in clinical settings are likely to be equally effective in the short-term treatment of people with panic disorders.

Type
Original Articles
Information
Psychological Medicine , Volume 21 , Issue 4 , November 1991 , pp. 991 - 998
Copyright
Copyright © Cambridge University Press 1991

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Balestrieri, M., Williams, P. & Wilkinson, G. (1988). Specialist mental health treatment in general practice: a meta-analysis. Psychological Medicine 18, 711–717.CrossRefGoogle ScholarPubMed
Balestrieri, M., Ruggeri, M. & Bellantuono, C. (1990). Drug treatment of panic disorder: a critical review of controlled clinical trials. Psychiatric Developments 4, 337–350.Google Scholar
Ballenger, J. C., Burrows, G. D., DuPont, R. L., Lesser, I. M., Noyes, R., Pecknold, J. C., Rifkin, A. & Swinson, R. P. (1988). Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. Archives of General Psychiatry 45, 413–422.CrossRefGoogle ScholarPubMed
Begg, C. B. (1985). A measure to aid in the interpretation of published clinical trials. Statistics in Medicine 4, 1–9.CrossRefGoogle ScholarPubMed
Chalmers, T. C., Levin, H., Sacks, H. S., Reitman, D., Berrier, J. & Nagalingam, R. (1987). Meta-analysis of clinical trials as a scientific discipline. I: control of bias and comparison with large cooperative trials. Statistics in Medicine 6, 315–325.CrossRefGoogle Scholar
Charney, D. S., Woods, S. W., Goodman, W. K., Rifkin, B., Kinch, M., Aiken, B., Quadrino, L. M. & Heninger, G. R. (1986). Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam and trazodone. Journal of Clinical Psychiatry 47, 580–586.Google ScholarPubMed
Chouinard, G., Annable, L., Fontaine, R. & Solyom, L. (1982). Alprazolam in the treatment of generalized anxiety and panic disorders. A double-blind placebo-controlled study. Psychopharmacology 77, 229–233.CrossRefGoogle ScholarPubMed
Dunner, D. L., Ishiki, D., Avery, D. H., Wilson, L. G. & Hyde, T. S. (1986). Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study. Journal of Clinical Psychiatry 47, 458–460.Google ScholarPubMed
Evans, L., Kenardy, J., Shneider, P. & Hoey, H. (1986). Effect of a selective serotonin uptake inhibitor in agoraphobia with panic attacks. Acta Psychiatrica Scandinavica 73, 49–53.CrossRefGoogle ScholarPubMed
Food and Drug Administration (1987). Xanax for Panic Disorder (NDA 18–276/5–015/5–017). Food and Drug Administration: Rockville, MD.Google Scholar
Gardner, M. J., Gardner, S. B. & Winter, P. D. (1989). Confidence Interval Analysis (CIA). Microcomputer Program Manual. British Medical Journal: London.Google Scholar
Glass, G. V. (1978). In defence of generalization. Behavioral and Brain Sciences 3, 394–395.CrossRefGoogle Scholar
Glass, C. V., McGaw, B. & Smith, M. L. (1981). Meta-analysis in Social Research. Sage Publications: Beverly Hills.Google Scholar
Hedges, L. V. (1981). Distribution theory for Glass's estimator of effect size and related estimators. Journal of Educational Statistics 6, 107–128.CrossRefGoogle Scholar
Klein, D. F. (1964). Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia 5, 397–408.CrossRefGoogle ScholarPubMed
Klein, D. F. & Oaks, G. (1967). Importance of psychiatric diagnosis in prediction of clinical drug effects. Archives of General Psychiatry 16, 118–126.CrossRefGoogle ScholarPubMed
Klerman, G. L., Ballenger, J. C., Burrows, G. D., DuPont, R. L., Noyes, R., Pecknold, J. C., Rifkin, A., Rubin, R. T. & Swinson, R. P. (1989). The ‘efficacy’ of alprazolam in panic disorder and agoraphobia: a critique of recent reports (letter). Archives of General Psychiatry 46, 670–672.Google Scholar
Lamb, W. K. & Witla, D. K. (1983). Meta-analysis and the integration of research findings: a trend analysis and bibliography prior to 1983. Research report, Harvard University, Cambridge Mass.: cited by Rosenthal (1984).Google Scholar
Lush, J. L. (1931). Predicting gains in feeder cattle and pigs. Journal of Agricultural Research 42, 853–881.Google Scholar
Mavissakalian, M. & Michelson, L. (1986). Agoraphobia: relative and combined effectivness of therapist-assisted in vivo exposure and imipramine. Journal of Clinical Psychiatry 47, 117–122.Google Scholar
Marks, I. M., Gray, S., Cohen, D., Hill, R., Mawson, D., Ramm, E. & Stern, R. (1983). Imipramine and brief therapist-aided exposure in agoraphobics having self-exposure homework. Archives of General Psychiatry 40, 153–162.CrossRefGoogle ScholarPubMed
Marks, I., De Albuquerque, A., Cottraux, J., Gentil, V., Greist, J., Hand, I., Liberman, R. L., Relvas, J. S., Tobena, A., Tyrer, P. & Wittchen, H. U. (1989). The ‘efficacy’ of alprazolam in panic disorder and agoraphobia: a critique of recent reports (letter). Archives of General Psychiatry 46, 668–670.Google Scholar
Munjack, D. J., Crocker, B., Cabe, D., Brown, R., Usigli, R., Zulueta, A., McManus, M., McDowell, D., Palmer, R. & Leonard, M. (1989). Alprazolam, propanolol and placebo in the treatment of panic disorder and agoraphobia with panic attacks. Journal of Clinical Psychopharmacology 9, 22–27.CrossRefGoogle ScholarPubMed
Peto, R. (1987). Why do we need systematic overviews of randomized trials? Statistics in Medicine 6, 233–240.CrossRefGoogle ScholarPubMed
Prioleau, L., Murdock, M. & Brody, N. (1983). An analysis of psychotherapy versus placebo studies. Behavioral and Brain Sciences 6, 275–310.CrossRefGoogle Scholar
Rosenthal, R. (1979). The ‘file drawer problem’ and tolerance for null results. Psychological Bulletin 86, 638–641.CrossRefGoogle Scholar
Rosenthal, R. (1984). Meta-analytic Procedures for Social Research. Sage Publications: Beverly Hills.Google Scholar
Rosenthal, R. & Rubin, D. B. (1982). A simple, general purpose display of magnitude of experimental effect. Journal of Educational Psychology 74, 166–169.CrossRefGoogle Scholar
Sheehan, D. V., Ballenger, J. & Jacobsen, G. (1980) Treatment of endogenous anxiety with phobic, hysterical, and hypocondriacal symptoms. Archives of General Psychiatry 37, 51–59.CrossRefGoogle Scholar
Smith, M. L. & Glass, G. V. (1977). Meta-analysis of psychotherapy outcome studies. American Psychologist 32, 752–760.CrossRefGoogle ScholarPubMed
Smith, M. L., Glass, G. V. & Miller, T. I. (1980). The Benefits of Psychotherapy. John Hopkins University Press: Baltimore.Google Scholar
Telch, M. J., Agras, S., Taylor, C. B., Roth, W. T. & Gallen, C. (1985). Combined pharmacological and behavioural treatment for agoraphobia. Behaviour Research and Therapy 23, 325–335.CrossRefGoogle ScholarPubMed
Tesar, G. E., Rosenbaum, J. F., Pollack, M. H., Herman, J. B., Sachs, G. S., Mahoney, E. M., Cohen, L. S., McNamara, M. & Goldstein, S. (1987). Clonazepam versus alprazolam in the treatment of panic disorder: interim analysis of data from a prospective, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 48 (Suppl. 10), 16–19.Google ScholarPubMed
Thorndike, R. L. (1933). The effect of the interval between test and retest on the constancy of the IQ. Journal of Educational Psychology 24, 543–549.CrossRefGoogle Scholar
Zitrin, C. M., Klein, D. F. & Woerner, M. G. (1978). Behavior therapy, supportive psychotherapy, imipramine, and phobias. Archives of General Psychiatry 35, 307–316.CrossRefGoogle ScholarPubMed
Zitrin, C. M., Klein, D. F. & Woerner, M. G. (1980). Treatment of agoraphobia with group exposure in vivo and imipramine. Archives of General Psychiatry 37, 63–73.CrossRefGoogle ScholarPubMed
Zitrin, C. M., Klein, D. F., Woerner, M. G. & Ross, D. C. (1983). Treatment of phobias. I. Comparison of imipramine hydrocloride and placebo. Archives of General Psychiatry 40, 125–138.CrossRefGoogle Scholar